GT929 Non-hodgkin’s lymphoma

On July 24, 2023, the molecular glue degrader GT929 developed by Gluetacs was approved by Center for Drug Evaluation, NMPA to enter the phase I/IIa clinical trial. On March 6, 2024, GT929 was announced dosing of the first patient in the phase I/IIa clinical trial.
Recruitment criteria:

You may be selected for this study if you meet the following key criteria:

  1. Male or female,over 18 years old;
  2. Patients diagnosed with relapsed or refractory non-Hodgkin lymphoma (rrNHL);
  3. ECOG score physical status <2, expected survival >12 weeks;
  4. Have adequate organ function, including blood system, liver function, kidney function, coagulation function, etc.;
  5. Subjects of reproductive age should agree to use effective contraception from the date of signing the informed consent until 6 months after the last dosing.

    Research Center:

    Fudan University Shanghai Cancer Center (Director Tao Rong; Director Zhang Jian)
    Sun Yat-Sen University Cancer Center(Director Cai Qingqing)
    The Affiliated Hospital of Xuzhou Medical University (Director Zhu Feng)